Cited by 195Antibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyUrinary Tract Infections Management

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms

Open access

Wu, Janet Y., Srinivas, Pavithra, Pogue, Jason M.·2020·Infectious Diseases and Therapy

DOI 10.1007/s40121-020-00286-6PMC PMC7054475

Open this paper in CoChat — free account Open PDF

Abstract

Cefiderocol, formerly S-649266, is a first in its class, an injectable siderophore cephalosporin that combines a catechol-type siderophore and cephalosporin core with side chains similar to cefepime and ceftazidime. This structure and its unique mechanism of action confer enhanced stability against hydrolysis by many β-lactamases, including extended spectrum β-lactamases such as CTX-M, and carbapenemases such as KPC, NDM, VIM, IMP, OXA-23, OXA-48-like, OXA-51-like and OXA-58. Cefiderocol's spectrum of activity encompasses both lactose-fermenting and non-fermenting Gram-negative pathogens, including carbapenem-resistant Enterobacterales. Cefiderocol recently received US Food and Drug Administration approval for the treatment of complicated urinary tract infections, including pyelonephritis, and is currently being evaluated in phase III trials for nosocomial pneumonia and infections caused by carbapenem-resistant Gram-negative pathogens. The purpose of this article is to review existing data on the mechanism of action, microbiology, pharmacokinetics, pharmacodynamics, efficacy, and safety of cefiderocol to assist clinicians in determining its place in therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s40121-020-00286-6

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Iron in infection and immunity
Cassat, J. E., & Skaar, E. P. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.04.010 · Cited by 1,214
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
Rodríguez‐Baño, J., Gutiérrez‐Gutiérrez, B., Machuca, I., & Pascual, Á. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 718
Identification of Acinetobacter baumannii by Detection of the bla OXA-51-like Carbapenemase Gene Intrinsic to This Species
Turton, J. F., Woodford, N., Glover, J., Yarde, S., Kaufmann, M. E., & Pitt, T. L. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01021-06 · Cited by 658
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
van Duin, D., Lok, J. J., Earley, M. J., Cober, E., Richter, S. S., Pérez, F., Salata, R. A., Kalayjian, R. C., Watkins, R., Doi, Y., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix783 · Cited by 657
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé, É., Woerther, P., & Barbier, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0061-0 · Cited by 523
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00883-17 · Cited by 496
Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Wunderink, R. G., Giamarellos‐Bourboulis, E. J., Rahav, G., Mathers, A. J., Bassetti, M., Vázquez, J. A., Cornely, O. A., Solomkin, J. S., Bhowmick, T., Bishara, J., et al. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0214-1 · Cited by 464
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
Zhanel, G. G., Golden, A. R., Zelenitsky, S., Wiebe, K., Lawrence, C. K., Adam, H. J., Idowu, T., Domalaon, R., Schweizer, F., Zhanel, M. A., et al. (2019) · Drugs · doi:10.1007/s40265-019-1055-2 · Cited by 446
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv050 · Cited by 436
Self-citation
Synthesis, nature and utility of universal iron chelator – Siderophore: A review
Khan, A., Singh, P., & Srivastava, A. (2017) · Microbiological Research · doi:10.1016/j.micres.2017.10.012 · Cited by 430
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Motsch, J., de Oliveira, C. M., Stus, V. P., Köksal, İ., Lyulko, O. O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz530 · Cited by 424
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Portsmouth, S., van Veenhuyzen, D., Echols, R., Machida, M., Ferreira, J. C. A., Ariyasu, M., Tenke, P., & Nagata, T. D. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30554-1 · Cited by 420
In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
Ito, A., Sato, T., Oota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 411
Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa
Rodríguez-Martínez, J. M., Poirel, L., & Nordmann, P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00574-09 · Cited by 307
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Hackel, M., Tsuji, M., Yamano, Y., ECHOLS, R. M., Karlowsky, J. A., & Sahm, D. F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01968-17 · Cited by 237
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa
Pogue, J. M., Kaye, K. S., Veve, M. P., Patel, T. S., Gerlach, A. T., Davis, S. L., Puzniak, L., File, T. M., Olson, S., Dhar, S., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz816 · Cited by 207
Self-citation
Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
Ito-Horiyama, T., Ishii, Y., Ito, A., Sato, T., Nakamura, R., Fukuhara, N., Tsuji, M., Yamano, Y., Yamaguchi, K., & Tateda, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03098-15 · Cited by 188
Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
McKinnell, J. A., Dwyer, J. P., Talbot, G. H., Connolly, L. E., Friedland, I. R., Smith, A., Jubb, A. M., Serio, A. W., Krause, K. M., & Daikos, G. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1807634 · Cited by 179
In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
Karlowsky, J. A., Hackel, M., Tsuji, M., Yamano, Y., ECHOLS, R. M., & Sahm, D. F. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.007 · Cited by 149
Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity
Chaudhry, S. B., Veve, M. P., & Wagner, J. L. (2019) · Pharmacy · doi:10.3390/pharmacy7030103 · Cited by 146
Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
Saisho, Y., Katsube, T., White, S., Fukase, H., & Shimada, J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02163-17 · Cited by 124
In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models
Nakamura, R., Ito-Horiyama, T., Takemura, M., Toba, S., Matsumoto, S., Ikehara, T., Tsuji, M., Sato, T., & Yamano, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02031-18 · Cited by 119
ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
Jacobs, M. R., Abdelhamed, A. M., Good, C. E., Rhoads, D. D., Hujer, K. M., Hujer, A. M., Domitrovic, T., Rudin, S. D., Richter, S. S., van Duin, D., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01801-18 · Cited by 108
Cefiderocol, a Siderophore Cephalosporin for Gram‐Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
Katsube, T., ECHOLS, R. M., Ferreira, J. C. A., Krenz, H., Berg, J. K., & Galloway, C. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.841 · Cited by 106
Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
Matsumoto, S., Singley, C. M., Hoover, J. L., Nakamura, R., ECHOLS, R. M., Rittenhouse, S. F., Tsuji, M., & Yamano, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00700-17 · Cited by 101
Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model
Monogue, M. L., Tsuji, M., Yamano, Y., ECHOLS, R. M., & Nicolau, D. P. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01022-17 · Cited by 101
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function
Katsube, T., Wajima, T., Ishibashi, T., Ferreira, J. C. A., & ECHOLS, R. M. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01381-16 · Cited by 86
Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy
Kim, A., Kutschke, A., Ehmann, D. E., Patey, S. A., Crandon, J. L., Gorseth, E., Miller, A. A., McLaughlin, R. E., Blinn, C. M., Chen, A., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00831-15 · Cited by 77
Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
Katsube, T., Saisho, Y., Shimada, J., & Furuie, H. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz123 · Cited by 75
Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
Ito, A., Nishikawa, T., Oota, M., Ito-Horiyama, T., Ishibashi, N., Sato, T., Tsuji, M., & Yamano, Y. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky317 · Cited by 74
Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient
Alamarat, Z. I., Babic, J. T., Tran, T. T., Wootton, S. H., Dinh, A. Q., Miller, W. R., Hanson, B., Wanger, A. R., Gary, J. L., Arias, C. A., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01872-19 · Cited by 65
Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa
Edgeworth, J. D., Merante, D., Patel, S. V., Young, C., Jones, P., Vithlani, S., Wyncoll, D. L. A., Roberts, P., Jones, A., Nagata, T. D., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy963 · Cited by 64
Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report
Trecarichi, E. M., Quirino, A., Scaglione, V., Longhini, F., Garofalo, E., Bruni, A., Biamonte, E., Lionello, R., Serapide, F., Mazzitelli, M., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz318 · Cited by 62
Stability of cefiderocol against clinically significant broad-spectrum oxacillinases
Poirel, L., Kieffer, N., & Nordmann, P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.005 · Cited by 58
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
Kawaguchi, N., Katsube, T., ECHOLS, R. M., & Wajima, T. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01391-17 · Cited by 57
Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model
Ghazi, I. M., Monogue, M. L., Tsuji, M., & Nicolau, D. P. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.10.008 · Cited by 50
Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug‐Resistant Pseudomonas aeruginosa : A Case Report
Stevens, R. W., & Clancy, M. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2334 · Cited by 42
Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa
Ghazi, I. M., Monogue, M. L., Tsuji, M., & Nicolau, D. P. (2018) · Pharmacology · doi:10.1159/000487441 · Cited by 41
Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters
Katsube, T., Miyazaki, S., Narukawa, Y., Hernandez‐Illas, M., & Wajima, T. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2458-9 · Cited by 29
696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies
Ito, A., Nishikawa, T., Ishii, R., Kuroiwa, M., Ishioka, Y., Kurihara, N., Sakikawa, I., Ota, T., Rokushima, M., Tsuji, M., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy210.703 · Cited by 29
Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
Stainton, S. M., Monogue, M. L., Tsuji, M., Yamano, Y., ECHOLS, R. M., & Nicolau, D. P. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01040-18 · Cited by 29
Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects
Sanabria, C. R., Migoya, E. M., Mason, J. W., Stanworth, S. H., Katsube, T., Machida, M., Narukawa, Y., & Nagata, T. D. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.07.006 · Cited by 28
Susceptibility of Imipenem-Susceptible but Meropenem-Resistant bla IMP-6 -Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol
Kanazawa, S., Sato, T., Kohira, N., Ito-Horiyama, T., Tsuji, M., & Yamano, Y. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00576-17 · Cited by 17
Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
Ito, A., Nishikawa, T., Oota, M., Ito-Horiyama, T., Ishibashi, N., Sato, T., Tsuji, M., & Yamano, Y. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky482 · Cited by 8

Sorted by citations

Pneumonia
Torres, A., Cillóniz, C., Niederman, M. S., Menéndez, R., Chalmers, J. D., Wunderink, R. G., & van der Poll, T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00259-0 · Cited by 904
Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race
Baran, A., Kwiatkowska, A., & Potocki, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065777 · Cited by 354
Update of the treatment of nosocomial pneumonia in the ICU
Zaragoza, R., Vidal, P., Aguilar, G., Borges-Sa, M., Dı́az, E., Ferrer, R., Maseda, E., Nieto, M., Nuvials, X., Ramírez, P., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03091-2 · Cited by 238
The Role of Five-Membered Heterocycles in the Molecular Structure of Antibacterial Drugs Used in Therapy
Rusu, A., Moga, I., Uncu, L., & Hancu, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112554 · Cited by 230
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens
Saxena, D., Maitra, R., Bormon, R., Czekanska, M., Meiers, J., Titz, A., Verma, S., & Chopra, S. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00016-1 · Cited by 217

See all 195

Authors: Wu, J. Y., Srinivas, P., & Pogue, J. M.
Affiliations: Cleveland Clinic (US)
University of Michigan (US)
Corresponding author: Wu, Janet Y.
ORCID: Wu, Janet Y.
Srinivas, Pavithra
Pogue, Jason M.
Venue: Infectious Diseases and Therapy
Publisher: Springer Science and Business Media LLC
Published: 2020-02-18
Volume: 9
Issue: 1
Pages: 17-40
ISSN: 2193-6382 (ISSN-L)
2193-8229
DOI: 10.1007/s40121-020-00286-6
PMC: PMC7054475
OpenAlex: W3008901682
Cited by: 195
References: 45
Citations by year: 2026: 25 · 2025: 25 · 2024: 25 · 2023: 37 · 2022: 36 · 2021: 28 · 2020: 18
FWCI: 2.10
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc
creativecommons.org/licenses/by-nc/4.0 (tdm)
creativecommons.org/licenses/by-nc/4.0 (vor)
Locations: Infectious Diseases and Therapy (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Health Sciences › Medicine › Urology › Urinary Tract Infections Management
Keywords: cefiderocol, siderophore cephalosporin, multidrug-resistant Gram-negative bacteria, carbapenem resistance, extended-spectrum beta-lactamase, carbapenemase, mechanism of action, pharmacokinetics, pharmacodynamics, complicated urinary tract infection, nosocomial pneumonia, Enterobacterales, drug safety and efficacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks